Rep. Julie Johnson bought Charles River Laboratories International (CRL)
Rep. Julie Johnson (D-TX-32) · $1K–$15K · traded Jan 15, 2025
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Joint
- Traded
- Jan 15, 2025
- Disclosed
- Feb 12, 2025
- Days to disclose
- 28
- Asset type
- Stock
- As filed
- Charles River Laboratories International, Inc. Common Stock
- Industry
- Medical - Diagnostics & Research · Healthcare
Other trades in this filing
All of Johnson's trades →- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 28, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 28, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 28, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 28, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 27, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 24, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
Sold (partial) Chubb Limited CB
$1K–$15K · Traded Jan 24, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
Sold (partial) Morgan Stanley MS
$1K–$15K · Traded Jan 24, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
Bought The Goldman Sachs Group GS
$1K–$15K · Traded Jan 24, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 17, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 17, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
Sold (partial) Monster Beverage MNST
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Feb 12, 2025$1K–$15K
Bought Walgreens Boots Alliance WBA
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
Recent Congress trades in CRL
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Charles River Laboratories International CRL
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- May 8, 2025$15K–$50K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Dec 5, 2024$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Nov 15, 2024 · disclosed Dec 5, 2024
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Oct 2, 2023 · disclosed Nov 8, 2023
- Oct 10, 2023$1K–$15K
Rep. Lois Frankel (D-FL-22)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
- May 19, 2023$1K–$15K
Rep. Lois Frankel (D-FL-22)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Apr 25, 2023 · disclosed May 19, 2023
Company context for CRL
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
CRL: third_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Oct 20, 2026, 9:28 PM EDTOriginal source ↗CRL: second_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Jul 20, 2026, 10:36 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.